2 recruiting, 1 not yet recruiting. 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Recruiting 2, Not yet recruiting 1 |
Follow DLBCL - Diffuse Large B Cell Lymphoma: new trials by email Literature Review of DLBCL - Diffuse Large B Cell Lymphoma trials Research Report on DLBCL - Diffuse Large B Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL Orelabrutinib Combined with Pola-R-CHP Regimen - DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-08-30 | 2026-08-21 |
| Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide, Rituximab+Gemcitabine+Oxaliplatin - DLBCL - Diffuse Large B Cell Lymphoma | Not applicable | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 70 | 2026-02-25 | 2026-02-05 |
| Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers Hematolo-GIST Training, Participants Appointment - Lymphoma, B-Cell, Lymphoma | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 48 | 2023-07-03 | 2026-10-13 |
Dendritic Cell Sarcoma, Interdigitating (3) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1)
Hemic and Lymphatic Diseases (3) · Histiocytic Disorders, Malignant (3) · Histiocytosis (3) · Lymphatic Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1)
Cyclophosphamide (1) · Doxorubicin (1) · Prednisone (1) · Rituximab (1) · orelabrutinib (1) · polatuzumab vedotin (1)
Memorial Sloan Kettering Cancer Center (1) · The First Affiliated Hospital of Xiamen University (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (1) · United States (1)
Bing Xu, PhD,MD (1) · Jinhua Liang (1) · Kelly McConnell, PhD (1) · Wei Xu (1)